广州医科大学学报
廣州醫科大學學報
엄주의과대학학보
Academic Journal of Guangzhou Medical College
2015年
4期
76-78
,共3页
舒张性心力衰竭%螺内脂%地尔硫卓%倍他乐克
舒張性心力衰竭%螺內脂%地爾硫卓%倍他樂剋
서장성심력쇠갈%라내지%지이류탁%배타악극
diastolic heart failure%spironolactone%diltiazem%betaloc
目的::探讨螺内脂联合地尔硫卓治疗舒张性心力衰竭的临床效果。方法:将2013年6月至2014年6月化州市人民医院收治的120例舒张性心力衰竭患者分为对照组(螺内酯联合倍他乐克)和研究组(螺内酯联合地尔硫卓),每组各60例。对比两组治疗前后E峰、A峰、E/A比值、6 min步行距离、脑钠肽水平灯指标的差异。结果:治疗前两组E峰、A峰、E/A比值、6 min步行距离、脑钠肽水平比较,差异无统计学意义(P>0.05);治疗后,两组上述指标优于治疗前,且研究组优于对照组(P<0.05)。结论:螺内脂联合地尔硫卓治疗舒张性心力衰竭,可有效改善患者的舒张性心功能不全,效果良好,值得推广应用。
目的::探討螺內脂聯閤地爾硫卓治療舒張性心力衰竭的臨床效果。方法:將2013年6月至2014年6月化州市人民醫院收治的120例舒張性心力衰竭患者分為對照組(螺內酯聯閤倍他樂剋)和研究組(螺內酯聯閤地爾硫卓),每組各60例。對比兩組治療前後E峰、A峰、E/A比值、6 min步行距離、腦鈉肽水平燈指標的差異。結果:治療前兩組E峰、A峰、E/A比值、6 min步行距離、腦鈉肽水平比較,差異無統計學意義(P>0.05);治療後,兩組上述指標優于治療前,且研究組優于對照組(P<0.05)。結論:螺內脂聯閤地爾硫卓治療舒張性心力衰竭,可有效改善患者的舒張性心功能不全,效果良好,值得推廣應用。
목적::탐토라내지연합지이류탁치료서장성심력쇠갈적림상효과。방법:장2013년6월지2014년6월화주시인민의원수치적120례서장성심력쇠갈환자분위대조조(라내지연합배타악극)화연구조(라내지연합지이류탁),매조각60례。대비량조치료전후E봉、A봉、E/A비치、6 min보행거리、뇌납태수평등지표적차이。결과:치료전량조E봉、A봉、E/A비치、6 min보행거리、뇌납태수평비교,차이무통계학의의(P>0.05);치료후,량조상술지표우우치료전,차연구조우우대조조(P<0.05)。결론:라내지연합지이류탁치료서장성심력쇠갈,가유효개선환자적서장성심공능불전,효과량호,치득추엄응용。
Objective:To investigate the clinical effect of Spironolactone and Diltiazem for treatment of diastolic heart failure (DHF). Methods: A total of 120 patients with DHF hospitalized in Huazhou Municipal People′s Hospital between June 2013 and June 2014 were included in the study, and divided into the control group (Spironolactone and Betaloc) and the study group (Spironolactone and Diltiazem) (n=60 each). The differences in the E peak, A peak, E/A ratio, 6 min walking distance, and brain natriuretic peptide ( BNP ) level between the two groups before and after the treatment were compared. Results: There were no statistically significant differences in the E peak, A peak, E/A ratio, 6 min walking distance, and BNP level between the two groups before the treatment ( P>0. 05 ) . These parameters of the two groups after the treatment were significantly better than those before the treatment, and the study group was superior to the control group ( P<0. 05) . Conclusion: Spironolactone and Diltiazem can be used to treat DHF, which can effectively improve diastolic cardiac insufficiency, and justifies widespread use.